Kevin Lumb

Kevin Lumb has extensive experience in the pharmaceutical and biotechnology industry. Kevin is currently serving as the Vice President of Discovery Sciences at Monte Rosa Therapeutics since 2023. Prior to this, they held the position of Vice President of Biology at Avilar Therapeutics from 2021 to 2023.

From 2014 to 2020, Lumb worked at The Janssen Pharmaceutical Companies of Johnson & Johnson, where they served as the Global Head of Lead Discovery & Profiling in the Discovery Sciences division. Before that, they held the role of Scientific Director of Emerging Science & Innovation in the same division from 2014 to 2016.

Lumb's earlier experience includes various leadership roles at Merck & Co. from 2007 to 2014, including Department Head of Protein Science, Biochemical Screening/Global Structural Biology, and Global Structural Biology.

Kevin began their career at Bayer in 2002, where they worked as a Principal Scientist and later as a Senior Scientist in Research Technologies. During this time, Lumb played a significant role in several metabolic disease area programs, peptide chemistry, and protein biomarker exploration.

Overall, Lumb has a strong track record of leadership and expertise in various aspects of drug discovery and development, with a focus on discovery sciences.

Kevin Lumb holds a Doctor of Philosophy (D.Phil.) degree in Biophysics and Structural Biology from the University of Oxford, where they were advised by Sir Christopher M. Dobson FRS. Kevin also completed a postdoctoral research program in Biophysics and Structural Biology at the Whitehead Institute at MIT, under the mentorship of Peter S. Kim. In addition, they earned a Bachelor of Science with Honours (B.Sc.) in Chemistry from UCL. Kevin Lumb has also obtained additional certifications in "The Business of Biotechnology" from RA Capital Management, L.P. in 2021, and in Six Sigma Green Belt (CSSGB) from Merck in 2008.